Skip to content

US · CVKD · BIOTECHNOLOGY

Cadrenal Therapeutics, Inc. Common Stock (CVKD) intrinsic value and stock valuation

$1.70as of 2026-11-21 · Mkt cap 6.04M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cadrenal Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values CVKD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CVKD’s statements →

Cadrenal Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ponte Vedra, FL 32082 cadrenal.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-13.24M
20222025
Free cash flow
-$-12.6M
20222025
Total equity
$2.74M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-13.46M-$-10.96M-$-7.63M-$-2.7M
Net income-$-13.24M-$-10.65M-$-8.36M-$-6.71M
EPSd-$-6.65M-$-8.73M-$-9.61M-$-8.6M
Operating cash flow-$-12.6M-$-7.36M-$-3.53M-$-1.2M
Capital expenditure-$-10K-$-10K-$0.00$0.00
Free cash flow-$-12.6M-$-7.36M-$-3.53M-$-1.2M
Total assets$4.33M$10.1M$8.52M$780K
Total debt$0.00$0.00$20K$640K
Net debt-$-4.01M-$-10.02M-$-8.38M$610K
Total equity$2.74M$7.44M$7.69M-$-5.55M
Cash and short-term investments$4.01M$10M$8.4M$30K
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00-$0.00
Research and development expenses$4.1M$4.21M$4.08M$390K
Selling, general and administrative expenses$9.35M$6.75M$3.55M$2.31M
Other expenses$10K$0.00$0.00$0.00
Operating expenses$13.5M$11M$7.63M$2.7M
Cost and expenses$13.5M$11M$7.63M$2.7M
Interest income$220K$310K$250K$0.00
Interest expense$0.00$0.00$20K$110K
Depreciation and amortization$10K$0.00$0.00$0.00
Ebitda-$-13.23M-$-10.65M-$-8.34M-$-6.61M
Operating income-$-13.46M-$-10.96M-$-7.63M-$-2.7M
Total other income/expenses, net$220K$310K-$-720K-$-4.01M
Income before tax-$-13.24M-$-10.65M-$-8.36M-$-6.71M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-13.24M-$-10.65M-$-8.36M-$-6.71M
Weighted average shares outstanding$1.99M$1.22M$870K$780K
Weighted average diluted shares outstanding$1.99M$1.22M$870K$780K
Balance sheet
2025202420232022
Cash and short-term investments$4.01M$10M$8.4M$30K
Net receivables$10K$40K$40K$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$4.32M$10.1M$8.49M$730K
Property, plant and equipment, net$10K$10K$20K$40K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$10K$10K$30K$50K
Total assets$4.33M$10.1M$8.52M$780K
Accounts payable$650K$1.5M$170K$400K
Short-term debt$0.00$0.00$20K$70K
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$1.59M$2.68M$830K$1.33M
Long-term debt$0.00$0.00$0.00$570K
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$4.99M
Capital lease obligations$0.00$0.00$20K$40K
Total liabilities$1.59M$2.68M$830K$6.33M
Common stock$0.00$0.00$10K$10K
Retained earnings-$-38.96M-$-25.72M-$-15.07M-$-6.71M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00
Total equity$2.74M$7.44M$7.69M-$-5.55M
Total investments$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$20K$640K
Net debt-$-4.01M-$-10.02M-$-8.38M$610K
Cash flow statement
2025202420232022
Net income-$-13.24M-$-10.65M-$-8.36M-$-6.71M
Depreciation and amortization$10K$0.00$0.00$0.00
Stock-based compensation$1.94M$1.42M$710K$1.01M
Change in working capital-$-1.31M$1.87M$140K$610K
Accounts receivable$30K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-850K$1.34M-$-240K$400K
Net cash provided by operating activities-$-12.6M-$-7.36M-$-3.53M-$-1.2M
Investments in property, plant and equipment-$-10K-$-10K-$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-10K-$0.00-$0.00
Common stock issued$7.16M$5.14M$11.9M$1.24M
Common stock repurchased-$-290K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.6M$8.98M$11.9M$1.24M
Net change in cash-$-6.01M$1.62M$8.37M$30K
Cash at end of period$4.01M$10M$8.4M$30K
Operating cash flow-$-12.6M-$-7.36M-$-3.53M-$-1.2M
Capital expenditure-$-10K-$-10K-$0.00$0.00
Free cash flow-$-12.6M-$-7.36M-$-3.53M-$-1.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cadrenal Therapeutics, Inc. Common Stock

        Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

        CEO
        Quang X. Pham
        Employees
        5
        Beta
        1.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Cadrenal Therapeutics, Inc. Common Stock (CVKD)?

        InvestorsCraft does not currently publish an intrinsic value for CVKD. How the IC value is calculated.

        Is CVKD undervalued?

        InvestorsCraft does not publish an undervaluation signal for CVKD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.